Stay updated on Palbociclib With Standard Treatment in Residual Breast Cancer Clinical Trial

Sign up to get notified when there's something new on the Palbociclib With Standard Treatment in Residual Breast Cancer Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Palbociclib With Standard Treatment in Residual Breast Cancer Clinical Trial page

  1. Check
    yesterday
    No Change Detected
  2. Check
    2 days ago
    No Change Detected
  3. Check
    3 days ago
    No Change Detected
  4. Check
    4 days ago
    Change Detected
    Summary
    The study has expanded to include 11 locations, and the revision has been updated from v2.9.7 to v2.10.0.
    Difference
    0.2%
    Check dated 2024-07-23T14:35:36.000Z thumbnail image
  5. Check
    5 days ago
    No Change Detected
  6. Check
    11 days ago
    Change Detected
    Summary
    The website has been updated to Revision v2.9.7 from v2.9.6.
    Difference
    0.0%
    Check dated 2024-07-16T07:55:28.000Z thumbnail image
  7. Check
    25 days ago
    Change Detected
    Summary
    The value of Revision has been updated from v2.9.5 to v2.9.6, indicating a recent change in the webpage content.
    Difference
    0.0%
    Check dated 2024-07-02T14:29:39.000Z thumbnail image
  8. Check
    30 days ago
    Change Detected
    Summary
    The value of Revision has been updated from v2.9.3 to v2.9.5, indicating a recent change in the webpage content.
    Difference
    0.0%
    Check dated 2024-06-27T09:59:48.000Z thumbnail image
  9. Check
    31 days ago
    Change Detected
    Summary
    The value of Revision has been updated from v2.9.1 to v2.9.3, indicating a recent change in the webpage content.
    Difference
    0.0%
    Check dated 2024-06-26T08:47:51.000Z thumbnail image
  10. Check
    32 days ago
    Change Detected
    Summary
    The value 'Show more Show more Show more Revision: v2.9.0' has recently changed to 'Show less Show less MedlinePlus Genetics related topics: Breast cancer MedlinePlus related topics: Breast Cancer Hormones Drug Information available for: Palbociclib FDA Drug and Device Resources Show less Design Details Primary Purpose : Treatment Allocation : Randomized Interventional Model : Parallel Assignment Masking : Quadruple ( Participant Care Provider Investigator Outcomes Assessor ) Arms and Interventions Participant Group/Arm Intervention/Treatment Experimental : Palbociclib Palbociclib at a dose of 125 mg once daily, day 1 to day 21 followed by 7 days off treatment in a 28-day cycle for thirteen cycles Drug : Palbociclib PD-0332991 palbociclib at a dose of 125 mg once daily, day 1 to day 21 followed by 7 days off treatment in a 28-day cycle Other Names: Ibrance Placebo Comparator : Placebo Placebo of palbociclib once daily day 1 to day 21 followed by 7 days off treatment in a28-day cycle for thirteen cycles Drug : Placebo Arm B: Placebo of palbociclib once daily day 1 to day 21 followed by 7 days off treatment in a 28-day cycle for thirteen cycles Primary Outcome Measures Outcome Measure Measure Description Time Frame Invasive Disease Free Survival (iDFS) for Palbociclib vs. Placebo in Patients With High CPS-EG Score After Neoadjuvant Chemotherapy Receiving Standard Adjuvant Endocrine Therapy for HR-positive/HER2-normal Primary Breast Cancer. Invasive disease-free survival (iDFS) is defined according to Hudis (J Clin Oncol 2007) as the time period between randomization and first event (ipsi- or contralateral invasive in-breast or loco-regional recurrence, distant recurrence, death from breast cancer, death from non-breast cancer cause, death from unknown cause, invasive contralateral breast cancer, second primary invasive cancer (non-breast)) assessed until the end of study. From date of randomisation to data cut off: 24 August 2020 (approximately 6 years and 6 months) Secondary Outcome Measures Outcome Measure Measure Description Time Frame iDFS Excluding Second Non-breast Cancers Invasive disease-free survival (iDFS) is defined according to Hudis (J Clin Oncol 2007) as the time period between randomization and first event assessed until the end of study. From date of randomisation to data cut off: 24 August 2020 (approximately 6 years and 6 months) Distant Disease Free Survival (DDFS) Distant disease free survival (DDFS) is defined as the time period between randomization and diagnosis of first distant breast cancer recurrences assessed until the end of study. From date of randomisation to data cut off: 24 August 2020 (approximately 6 years and 6 months) Overall Survival (OS) Overall survival (OS) is defined as the time period between randomization and death of any cause assessed until the end of study. From date of randomisation to data cut off: 24 August 2020 (approximately 6 years and 6 months) Additional Relevant MeSH Terms Neoplasms by Site Neoplasms Breast Diseases Skin Diseases Breast Neoplasms Antineoplastic Agents Protein Kinase Inhibitors Enzyme Inhibitors Molecular Mechanisms of Pharmacological Action Palbociclib Study Documents Provided by German Breast Group Study Protocol [ PDF , 2.76MB, 2019-04-09 ] Statistical Analysis Plan [ PDF , 0.69MB, 2020-09-21 ] Informed Consent Form [ PDF , 0.3MB, 2017-05-04 ] Helpful Links Provided by German Breast Group General trial information Revision: v2.9.1'
    Difference
    13%
    Check dated 2024-06-25T08:23:12.000Z thumbnail image

Stay in the know with updates to Palbociclib With Standard Treatment in Residual Breast Cancer Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Palbociclib With Standard Treatment in Residual Breast Cancer Clinical Trial page.